According to the results of a new Phase 3 clinical trial (TRANSCEND-T2D-1) published in the renowned medical journal The Lancet, the experimental drug Retatrutide significantly reduced blood sugar levels and led to substantial weight loss in patients with type 2 diabetes. The trial of this weekly injectable medication involved adults who had not previously received other medical treatments and were attempting to control their sugar levels through diet and exercise alone.
Upon completion of the 40-week study, patients receiving Retatrutide experienced a reduction in glycated hemoglobin (HbA1c — a long-term measure of blood sugar) by an average of 1.7% to 1.9%, compared to a reduction of just 0.8% in the placebo group. Furthermore, participants taking the new drug lost an average of 11.5% to 15.3% of their body weight, significantly outperforming the placebo group’s result (2.6%).
Retatrutide belongs to a brand-new generation of weight loss and diabetes medications provisionally referred to as “GLP-3 agonists.” Unlike today’s widely used drugs (such as Ozempic or Wegovy), which primarily target only one or two hormonal receptors (GLP-1, or GLP-1 and GIP), Retatrutide simultaneously acts on three receptors involved in metabolism: GIP, GLP-1, and glucagon. Along with appetite suppression, the additional activation of the glucagon receptor increases the body’s energy expenditure, ultimately driving more effective weight loss.
According to scientists, this triple-acting medication has the potential to revolutionize the management of type 2 diabetes, particularly for patients requiring more intensive treatment. Additional studies are currently ongoing to definitively confirm the drug’s long-term safety and efficacy.
